Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Allscripts' Touchworks Users

Articles with lock require a subscription to GLG News | Request a free trial
November 26, 2008
Why hasn't EHR been adopted faster
Analysis of: Survey: Hospital EHR Adoption Rate is Below 12% | www.govhealthit.com
Author: John Hsu, Director of Anesthesiology , Presbyterian Intercommunity Hospital Inc
The lack of a comprehensive EHR implementation suggests that we are failing at our goal of improving the healthcare system.  While the article highlights many problems, very few solutions are offered to remedy this part of our healthcare crises. The key implications are: 1....
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
February 12, 2008
Cardinal Health has renewed focus and new leadership
Analysis of: Cardinal Health Could Be Regaining Its Strength | online.wsj.com
Author: GLG Expert Contributor
Cardinal Health with George Barrett as Vice Chairman has brought renewed focus on its medical supplies business. It has had early renewal of its contract with Walgreen and has increased generic portfolio with Cardiolite. Its generic drug distribution business has major growth potential.
February 7, 2008
Botulinum Toxin Type A has long-term efficacy and safety for glabellar skin lines
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: GLG Expert Contributor
The long term efficacy of botulinum toxin Type A for the treatment of glabellar frown lines was recently discussed  in San Antonio, Texas at the 66th annual meeting of the American Association of Dermatology. Kawashima and other fellow Japanese investigators presented long-term (64 weeks)...
November 23, 2007
Forteo increases bone but does it decrease fracture risk
Analysis of: Forteo Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis | pharmalive.com
Author: GLG Expert Contributor
Forteo is a very strong osteoporosis medication that is one of the only medications available that actually stimulates bone growth.  There are two types of cells in the bone (which is actually a living organ that remodels constantly over time) - Osteoblasts (bone builders) and Osteoclasts (bone...
November 16, 2007
Theword of mouth
Analysis of: Cigna reaches deal on doctors' rankings | news.yahoo.com
Author: John Hsu, Director of Anesthesiology , Presbyterian Intercommunity Hospital Inc
Missing in the article is the fact patients will still go to the physicians that they like regardless of the rating system.  This rating system of doctors is really economic credentialling.  Insurance companies will lower reimbursement unit values of physicians that are not rated...
November 6, 2007
New Glaucoma Product Should Simplify Patient Compliance and Increase Allergan's Share of Glaucoma Market
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
Patient compliance with glaucoma eyedrops is a key barrier in achieveing acceptable clinical outcomes. There is only one other product, Cosopt (by Merck) that offers a combination glaucoma medication. This medication may become a popular choice for glaucoma doctors to improve patient complian...
October 1, 2007
Pain has not killed anyone
Analysis of: FDA Warns About Misuse Of Fentora Cancer Pain Drug | www.medicalnewstoday.com
Author: John Hsu, Director of Anesthesiology , Presbyterian Intercommunity Hospital Inc
Because the FDA warns about the misuse Of Fentora as a Cancer Pain Drug,  I hope that physicians will be very carefull about prescribing this very potent opiate medication.  Fortunately, the company Cephalon is correcting the problem without taking away the important role of this drug...
September 17, 2007
EVISTA - the First for Breast Cancer Prevention and Osteoporosis Treatment..BUT
Analysis of: FDA approves Lilly's Evista for breast cancer | www.marketwatch.com
Author: GLG Expert Contributor
Evista sales may improve due to the FDA approval for both prevention of invasive breast cancer and osteoporosis but the increase is likely to be very modest.  It has advantages over tamoxifen in that Evista does not cause endometrial hyperplasia or cancer of the uterus, however it still carries...
September 7, 2007
Haven't physicians been lending "no-interest" money to payers and patients all along?
Analysis of: Doctors Offering No-Interest Loans to Patients | www.nytimes.com
Author: Richard Jung, Chief Operating Officer, Medsphere Systems Corporation
Does anyone else remember the time when your Mother would take you to the Dr. as a child? You'd sit on his knee, have a nice chat, get a shot or other, pick up your lollipop and say goodbye. Not even a copay was exchanged and the practice manager would say, "Don't worry, we'll file all the paperwork...

Page : 1 2 Next1 to 10 of 19

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637